Imap

Fluspirilene, the active ingredient in Imap, is a typical antipsychotic presented as an intramuscular injection for intramuscular use. It is indicated for the treatment of schizophrenia in adult patients and is marketed in the European Union. GNH USA supplies Imap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fluspirilene is a typical antipsychotic that acts on dopaminergic pathways to manage psychotic disorders.

Schizophrenia: reduces positive and negative symptoms in adult patients.

Common Side Effects: - Extrapyramidal symptoms (e.g., tremor, rigidity) - Sedation or drowsiness - Dry mouth - Constipation - Dizziness - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Agranulocytosis - Severe hypotension - Cardiac arrhythmias

Before initiating therapy, clinicians should consider the following precautions: - Monitor for extrapyramidal symptoms: assess motor function regularly. - Assess cardiovascular status: watch for hypotension or arrhythmias. - Avoid in patients with known hypersensitivity to fluspirilene or excipients. - Use caution in elderly patients with dementia-related psychosis: increased risk of mortality. - Do not discontinue abruptly: taper under medical supervision. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fluspirilene may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypotension. - Strong CYP2D6 inhibitors: increased plasma concentrations of fluspirilene. - Other dopamine antagonists: additive extrapyramidal effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may mask extrapyramidal symptoms. - Sedatives or hypnotics: enhanced central nervous system depression. - Alcohol: increased sedation and dizziness.